| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phospholipase D | 32 | 2019 | 47 | 7.980 |
Why?
|
| Sirolimus | 15 | 2021 | 58 | 5.040 |
Why?
|
| Phosphatidic Acids | 13 | 2023 | 18 | 4.870 |
Why?
|
| Neoplasms | 15 | 2022 | 1033 | 2.720 |
Why?
|
| Glutamine | 5 | 2022 | 31 | 2.520 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 183 | 2.280 |
Why?
|
| Protein Kinases | 9 | 2009 | 91 | 2.070 |
Why?
|
| Apoptosis | 17 | 2021 | 1317 | 1.960 |
Why?
|
| Multiprotein Complexes | 10 | 2017 | 53 | 1.840 |
Why?
|
| Cell Line, Tumor | 30 | 2021 | 2128 | 1.730 |
Why?
|
| Signal Transduction | 20 | 2021 | 1802 | 1.670 |
Why?
|
| Amino Acids | 5 | 2023 | 139 | 1.620 |
Why?
|
| ras Proteins | 6 | 2015 | 49 | 1.560 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2022 | 245 | 1.550 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 44 | 1.510 |
Why?
|
| Lysosomes | 2 | 2019 | 80 | 1.390 |
Why?
|
| Retinoblastoma Protein | 2 | 2021 | 27 | 1.350 |
Why?
|
| Cell Survival | 13 | 2018 | 818 | 1.260 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2016 | 41 | 1.240 |
Why?
|
| Phosphorylation | 15 | 2021 | 878 | 1.150 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2021 | 209 | 1.140 |
Why?
|
| Proteins | 5 | 2011 | 352 | 1.100 |
Why?
|
| Humans | 55 | 2023 | 34853 | 1.060 |
Why?
|
| Breast Neoplasms | 10 | 2015 | 1426 | 0.990 |
Why?
|
| G1 Phase | 3 | 2020 | 32 | 0.930 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2022 | 2 | 0.910 |
Why?
|
| Fibroblasts | 3 | 2020 | 252 | 0.890 |
Why?
|
| S Phase | 2 | 2020 | 36 | 0.880 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 117 | 0.840 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2020 | 89 | 0.830 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 29 | 0.820 |
Why?
|
| Transcription Factors | 4 | 2010 | 653 | 0.810 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 794 | 0.810 |
Why?
|
| Serum Albumin, Bovine | 1 | 2020 | 49 | 0.750 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2019 | 1 | 0.730 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2018 | 781 | 0.730 |
Why?
|
| Protein Kinase C | 5 | 2005 | 110 | 0.730 |
Why?
|
| Plant Oils | 1 | 2019 | 17 | 0.720 |
Why?
|
| Amino Acids, Essential | 1 | 2019 | 1 | 0.710 |
Why?
|
| Cell Membrane Permeability | 1 | 2019 | 49 | 0.710 |
Why?
|
| Aldehydes | 1 | 2019 | 65 | 0.690 |
Why?
|
| Ribosomal Protein S6 Kinases | 4 | 2013 | 9 | 0.680 |
Why?
|
| Phenols | 1 | 2019 | 76 | 0.670 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 35 | 0.670 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 184 | 0.670 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 105 | 0.650 |
Why?
|
| Animals | 24 | 2020 | 14307 | 0.630 |
Why?
|
| Cell Membrane | 3 | 2016 | 360 | 0.620 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 336 | 0.610 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2013 | 180 | 0.610 |
Why?
|
| ral GTP-Binding Proteins | 4 | 2018 | 8 | 0.580 |
Why?
|
| Eukaryotic Initiation Factor-4E | 2 | 2013 | 14 | 0.570 |
Why?
|
| Citric Acid Cycle | 1 | 2016 | 4 | 0.570 |
Why?
|
| Cell Movement | 4 | 2018 | 545 | 0.560 |
Why?
|
| Aspartic Acid | 1 | 2016 | 46 | 0.560 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 109 | 0.560 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2014 | 229 | 0.550 |
Why?
|
| Up-Regulation | 2 | 2018 | 490 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2006 | 52 | 0.550 |
Why?
|
| Glucose | 3 | 2014 | 217 | 0.550 |
Why?
|
| Ribonucleotides | 1 | 2015 | 4 | 0.530 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2015 | 4 | 0.530 |
Why?
|
| Glutamic Acid | 1 | 2016 | 115 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2010 | 39 | 0.520 |
Why?
|
| Cell-Free System | 1 | 2014 | 15 | 0.510 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 49 | 0.510 |
Why?
|
| Second Messenger Systems | 1 | 2014 | 14 | 0.510 |
Why?
|
| Estrogens | 2 | 2006 | 190 | 0.500 |
Why?
|
| Molecular Biology | 1 | 2014 | 44 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 106 | 0.480 |
Why?
|
| Phosphoproteins | 3 | 2013 | 154 | 0.470 |
Why?
|
| Smad4 Protein | 1 | 2013 | 6 | 0.460 |
Why?
|
| Mammals | 1 | 2013 | 96 | 0.450 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 162 | 0.450 |
Why?
|
| Enzyme Activation | 7 | 2015 | 423 | 0.440 |
Why?
|
| Lipids | 1 | 2014 | 222 | 0.430 |
Why?
|
| Carrier Proteins | 3 | 2008 | 287 | 0.420 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2009 | 79 | 0.410 |
Why?
|
| Gene Expression | 1 | 2014 | 639 | 0.400 |
Why?
|
| Glycolysis | 1 | 2010 | 66 | 0.380 |
Why?
|
| Cell Line | 5 | 2020 | 1289 | 0.380 |
Why?
|
| Food | 1 | 2011 | 95 | 0.370 |
Why?
|
| Immediate-Early Proteins | 1 | 2010 | 45 | 0.370 |
Why?
|
| Cell Proliferation | 4 | 2018 | 1149 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 984 | 0.360 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 69 | 0.360 |
Why?
|
| Virology | 1 | 2009 | 7 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2009 | 200 | 0.340 |
Why?
|
| Mice | 11 | 2019 | 5668 | 0.340 |
Why?
|
| Gene Knockdown Techniques | 3 | 2014 | 161 | 0.340 |
Why?
|
| Mutation | 5 | 2021 | 1023 | 0.340 |
Why?
|
| Information Systems | 1 | 2008 | 14 | 0.330 |
Why?
|
| Morpholines | 3 | 2015 | 65 | 0.330 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 203 | 0.330 |
Why?
|
| ADP-Ribosylation Factors | 2 | 2011 | 12 | 0.330 |
Why?
|
| Protein Binding | 6 | 2016 | 913 | 0.330 |
Why?
|
| Chromones | 3 | 2015 | 51 | 0.330 |
Why?
|
| Cell Cycle | 3 | 2021 | 309 | 0.330 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 55 | 0.320 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 81 | 0.320 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 160 | 0.320 |
Why?
|
| Kidney Neoplasms | 3 | 2016 | 65 | 0.320 |
Why?
|
| Hospitals | 1 | 2008 | 86 | 0.310 |
Why?
|
| Clinical Competence | 1 | 2008 | 124 | 0.310 |
Why?
|
| Internet | 1 | 2008 | 204 | 0.290 |
Why?
|
| Culture Media, Serum-Free | 4 | 2007 | 40 | 0.280 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 490 | 0.270 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 42 | 0.270 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 152 | 0.250 |
Why?
|
| Oncogene Protein pp60(v-src) | 2 | 2004 | 8 | 0.250 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 756 | 0.250 |
Why?
|
| Diacylglycerol Kinase | 2 | 2014 | 2 | 0.240 |
Why?
|
| Insulin | 2 | 2020 | 224 | 0.240 |
Why?
|
| Models, Biological | 4 | 2010 | 642 | 0.240 |
Why?
|
| Cell Division | 5 | 2004 | 296 | 0.230 |
Why?
|
| Blotting, Western | 5 | 2007 | 834 | 0.230 |
Why?
|
| Oxaloacetates | 1 | 2022 | 2 | 0.230 |
Why?
|
| Ketoglutaric Acids | 1 | 2022 | 2 | 0.230 |
Why?
|
| Aminooxyacetic Acid | 1 | 2022 | 3 | 0.230 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2022 | 4 | 0.230 |
Why?
|
| Transaminases | 1 | 2022 | 7 | 0.230 |
Why?
|
| Genes, ras | 1 | 2003 | 22 | 0.230 |
Why?
|
| Oleic Acids | 1 | 2022 | 12 | 0.230 |
Why?
|
| Glutamates | 1 | 2022 | 21 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerases | 4 | 2013 | 72 | 0.220 |
Why?
|
| GTP Phosphohydrolases | 1 | 2003 | 29 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 10 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 480 | 0.220 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 211 | 0.210 |
Why?
|
| History, 21st Century | 2 | 2014 | 74 | 0.210 |
Why?
|
| E2F Transcription Factors | 1 | 2021 | 9 | 0.210 |
Why?
|
| Cells, Cultured | 4 | 2019 | 1442 | 0.210 |
Why?
|
| History, 20th Century | 2 | 2014 | 110 | 0.210 |
Why?
|
| Protein Transport | 3 | 2019 | 286 | 0.200 |
Why?
|
| Protein Kinase C-delta | 4 | 2005 | 14 | 0.200 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 239 | 0.200 |
Why?
|
| RNA, Small Interfering | 3 | 2008 | 391 | 0.200 |
Why?
|
| Pinocytosis | 1 | 2020 | 8 | 0.190 |
Why?
|
| Cattle | 2 | 2020 | 472 | 0.190 |
Why?
|
| Oxidative Stress | 1 | 2006 | 874 | 0.190 |
Why?
|
| Serum | 2 | 2013 | 13 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2013 | 107 | 0.180 |
Why?
|
| Necrosis | 1 | 2019 | 45 | 0.180 |
Why?
|
| Cell Death | 1 | 2020 | 260 | 0.180 |
Why?
|
| Endocytosis | 1 | 2019 | 104 | 0.170 |
Why?
|
| Cell Cycle Proteins | 3 | 2013 | 220 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 242 | 0.170 |
Why?
|
| Androgens | 1 | 2018 | 87 | 0.150 |
Why?
|
| Oleic Acid | 1 | 2017 | 19 | 0.150 |
Why?
|
| Phosphatidate Phosphatase | 1 | 1996 | 2 | 0.150 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 52 | 0.150 |
Why?
|
| Oncogenes | 2 | 2009 | 43 | 0.150 |
Why?
|
| United States | 3 | 2014 | 3894 | 0.150 |
Why?
|
| Epidermal Growth Factor | 1 | 1996 | 63 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 53 | 0.150 |
Why?
|
| Isoenzymes | 3 | 2003 | 149 | 0.140 |
Why?
|
| Purine Nucleotides | 1 | 2016 | 3 | 0.140 |
Why?
|
| Pyrimidine Nucleotides | 1 | 2016 | 4 | 0.140 |
Why?
|
| Male | 3 | 2021 | 18870 | 0.140 |
Why?
|
| Porphyrins | 2 | 2008 | 53 | 0.140 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2006 | 95 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2015 | 42 | 0.130 |
Why?
|
| Cell Line, Transformed | 3 | 2004 | 87 | 0.130 |
Why?
|
| Cerulenin | 1 | 2014 | 1 | 0.130 |
Why?
|
| Diphenylamine | 1 | 2014 | 1 | 0.130 |
Why?
|
| Fatty Acid Synthesis Inhibitors | 1 | 2014 | 1 | 0.130 |
Why?
|
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2014 | 1 | 0.130 |
Why?
|
| Lipogenesis | 1 | 2014 | 18 | 0.130 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2014 | 20 | 0.130 |
Why?
|
| Time Factors | 2 | 2013 | 1681 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 217 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 178 | 0.120 |
Why?
|
| Estradiol | 2 | 2006 | 244 | 0.120 |
Why?
|
| Garcinia | 1 | 2013 | 2 | 0.120 |
Why?
|
| Sulindac | 1 | 2013 | 7 | 0.120 |
Why?
|
| Benzophenones | 1 | 2013 | 7 | 0.120 |
Why?
|
| Benzamides | 1 | 2014 | 76 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2006 | 162 | 0.120 |
Why?
|
| Acyltransferases | 1 | 2013 | 21 | 0.120 |
Why?
|
| 3T3 Cells | 2 | 2003 | 58 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 2 | 2013 | 101 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2006 | 486 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 286 | 0.100 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2010 | 14 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2011 | 57 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2013 | 250 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 1 | 2010 | 49 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2015 | 1349 | 0.100 |
Why?
|
| Enzyme Stability | 1 | 2010 | 30 | 0.090 |
Why?
|
| Precipitin Tests | 2 | 2003 | 51 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 396 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2007 | 897 | 0.090 |
Why?
|
| Female | 3 | 2017 | 19873 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2013 | 122 | 0.090 |
Why?
|
| Retroviridae | 1 | 2009 | 22 | 0.090 |
Why?
|
| Transfection | 2 | 2007 | 496 | 0.090 |
Why?
|
| Personal Health Services | 1 | 2008 | 3 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 1 | 2008 | 12 | 0.080 |
Why?
|
| Information Services | 1 | 2008 | 14 | 0.080 |
Why?
|
| Knowledge | 1 | 2008 | 12 | 0.080 |
Why?
|
| Japan | 1 | 2009 | 296 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 52 | 0.080 |
Why?
|
| Lignans | 1 | 2008 | 21 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 40 | 0.080 |
Why?
|
| Rats | 3 | 2004 | 3261 | 0.080 |
Why?
|
| Protein Multimerization | 1 | 2008 | 97 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 195 | 0.080 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2007 | 5 | 0.080 |
Why?
|
| Light | 1 | 2008 | 180 | 0.080 |
Why?
|
| Length of Stay | 1 | 2008 | 184 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2007 | 57 | 0.070 |
Why?
|
| Phosphothreonine | 1 | 2006 | 5 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2008 | 183 | 0.070 |
Why?
|
| Medicare | 1 | 2008 | 188 | 0.070 |
Why?
|
| Phosphoserine | 1 | 2006 | 18 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2006 | 27 | 0.070 |
Why?
|
| Neurites | 1 | 2006 | 35 | 0.070 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2005 | 13 | 0.070 |
Why?
|
| Protein Phosphatase 2 | 1 | 2005 | 22 | 0.070 |
Why?
|
| Ribosomes | 1 | 2005 | 27 | 0.070 |
Why?
|
| Serine | 1 | 2005 | 72 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 126 | 0.070 |
Why?
|
| Guinea Pigs | 1 | 2005 | 141 | 0.070 |
Why?
|
| Thioglycosides | 1 | 2004 | 2 | 0.060 |
Why?
|
| DNA Damage | 2 | 2004 | 341 | 0.060 |
Why?
|
| Cricetinae | 1 | 2005 | 217 | 0.060 |
Why?
|
| Dogs | 1 | 2005 | 138 | 0.060 |
Why?
|
| Half-Life | 1 | 2004 | 52 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 341 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2004 | 37 | 0.060 |
Why?
|
| Tyrosine | 1 | 2004 | 109 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2003 | 18 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 72 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 182 | 0.060 |
Why?
|
| Cyclins | 1 | 2002 | 35 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 184 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 54 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 287 | 0.050 |
Why?
|
| Plasmids | 1 | 2003 | 233 | 0.050 |
Why?
|
| Disease Progression | 1 | 2004 | 580 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2003 | 420 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 145 | 0.050 |
Why?
|
| Kinetics | 1 | 2002 | 650 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 881 | 0.040 |
Why?
|
| Ethylmaleimide | 1 | 1996 | 8 | 0.040 |
Why?
|
| Glycosylation | 2 | 2008 | 92 | 0.040 |
Why?
|
| Presenilin-1 | 2 | 2006 | 27 | 0.040 |
Why?
|
| Curcuma | 1 | 2013 | 5 | 0.030 |
Why?
|
| Butadienes | 1 | 2013 | 30 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2013 | 9 | 0.030 |
Why?
|
| Heparin | 1 | 2013 | 34 | 0.030 |
Why?
|
| Nitriles | 1 | 2013 | 66 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 171 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2013 | 80 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2013 | 75 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 376 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 968 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 366 | 0.020 |
Why?
|
| Antibodies | 1 | 2009 | 135 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 80 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 45 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2008 | 86 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 114 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2008 | 100 | 0.020 |
Why?
|
| Caspases | 1 | 2008 | 132 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 210 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 240 | 0.020 |
Why?
|
| Diglycerides | 1 | 2007 | 10 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2007 | 25 | 0.020 |
Why?
|
| Type C Phospholipases | 1 | 2007 | 19 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 72 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2007 | 28 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2008 | 137 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 154 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2008 | 201 | 0.020 |
Why?
|
| Cell Communication | 1 | 2007 | 93 | 0.020 |
Why?
|
| trans-Golgi Network | 1 | 2006 | 3 | 0.020 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2006 | 33 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2006 | 58 | 0.020 |
Why?
|
| Catalysis | 1 | 2006 | 162 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 92 | 0.020 |
Why?
|
| Calcium | 1 | 2008 | 445 | 0.020 |
Why?
|
| Mitochondria | 1 | 2008 | 454 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2004 | 42 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2003 | 12 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2003 | 8 | 0.020 |
Why?
|
| K562 Cells | 1 | 2003 | 31 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 39 | 0.020 |
Why?
|
| Luciferases | 1 | 2003 | 62 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2003 | 139 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 121 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 522 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 597 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 1530 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 392 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 605 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 484 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 550 | 0.010 |
Why?
|